Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Rio

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 4, 2024
Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-A systematic review and meta-analysisChristoph Heesen, Christian Röver, Susanna Salem, et al.
Plos One|September 3, 2011
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosisSunny Malhotra, Marta F Bustamante, Francisco Pérez-Miralles, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2021
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With NatalizumabNicolás Fissolo, Beatrice Pignolet, Jordi Rio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2012
Analysis of prognostic factors associated with longitudinally extensive transverse myelitisMaría Sepúlveda, Yolanda Blanco, Alex Rovira, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 29, 2021
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosisSusana Otero-Romero, Pere Carbonell-Mirabent, Luciana Midaglia, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Neurology|March 6, 2024
Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseLuca Bollo, Georgina Arrambide, Alvaro Cobo-Calvo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 22, 2019
A pharmacogenetic study implicates <i>NINJ2</i> in the response to Interferon-β in multiple sclerosisSilvia Peroni, Melissa Sorosina, Sunny Malhotra, et al.
Annals of Neurology|September 14, 2023
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple SclerosisJavier Villacieros-Álvarez, Carmen Espejo, Georgina Arrambide, et al.
Neurology|July 19, 2023
Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating EventAlvaro Cobo-Calvo, Carmen Tur, Susana Otero-Romero, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 4, 2024
Treatment effect modifiers of immunotherapies for relapsing-remitting multiple sclerosis-A systematic review and meta-analysisChristoph Heesen, Christian Röver, Susanna Salem, et al.
Plos One|September 3, 2011
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosisSunny Malhotra, Marta F Bustamante, Francisco Pérez-Miralles, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2021
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With NatalizumabNicolás Fissolo, Beatrice Pignolet, Jordi Rio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 6, 2012
Analysis of prognostic factors associated with longitudinally extensive transverse myelitisMaría Sepúlveda, Yolanda Blanco, Alex Rovira, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 29, 2021
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosisSusana Otero-Romero, Pere Carbonell-Mirabent, Luciana Midaglia, et al.
Neurology|December 28, 2018
Unraveling treatment response in multiple sclerosis: A clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré, et al.
Neurology|March 6, 2024
Trans-Synaptic Degeneration in the Visual Pathway in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseLuca Bollo, Georgina Arrambide, Alvaro Cobo-Calvo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 22, 2019
A pharmacogenetic study implicates <i>NINJ2</i> in the response to Interferon-β in multiple sclerosisSilvia Peroni, Melissa Sorosina, Sunny Malhotra, et al.
Annals of Neurology|September 14, 2023
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple SclerosisJavier Villacieros-Álvarez, Carmen Espejo, Georgina Arrambide, et al.
Neurology|July 19, 2023
Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating EventAlvaro Cobo-Calvo, Carmen Tur, Susana Otero-Romero, et al.
Pageof 3